专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1990006123A1 THERAPEUTIC USE OF CALCIUM ENTRY BLOCKERS IN RETINAL OR OPTIC NERVE DYSFUNCTION 审中-公开
标题翻译：钙进入阻滞剂在视神经或神经功能障碍中的治疗应用
公开(公告)号：WO1990006123A1
公开(公告)日：1990-06-14
申请号：PCT/US1989005487
申请日：1989-12-05
申请人： HOUSTON BIOTECHNOLOGY INCORPORATED , CROSSON, Craig, E. , POTTER, David, E.
发明人： HOUSTON BIOTECHNOLOGY INCORPORATED
IPC分类号： A61K31/66
CPC分类号： A61K31/275 , A61K31/00 , A61K31/44 , A61K31/495 , A61K31/505 , A61K31/55 , A61K31/66
摘要： Ischemia or edema of the retina or optic nerve results in retinal dysfunction. This retinal dysfunction can be associated with the activation of calcium channels and/or excitatory amino acid receptors. The prophylactic or therapeutic administration of compounds to block these processes can ameliorate or prevent retinal dysfunction. These compounds include the classes of calcium channel antagonists. Therapeutic treatment with compounds include dihydropyridines and diphenylipiperazines as calcium channel antagonists. Such compounds also exhibit a prophylactic effect to ischemia and edema of the retina or optic nerve. Rat models are provided for screening compounds capable of ameliorating retinal dysfunction. Particularly, calcium entry blockers and excitatory amino acid antagonists can be screened and the host eyes examined for the effect of the drugs. The model animal is a rat having a salt-inducible retinal dysfunction and/or a retinal dysfunction as a result of vascular occlusion resulting in ischemia.
摘要翻译：视网膜或视神经缺血或水肿导致视网膜功能障碍。这种视网膜功能障碍可以与钙通道和/或兴奋性氨基酸受体的激活相关。阻止这些过程的化合物的预防或治疗性给药可以改善或预防视网膜功能障碍。这些化合物包括钙通道拮抗剂类。化合物的治疗性治疗包括二氢吡啶和二苯哌嗪作为钙通道拮抗剂。这些化合物还对视网膜或视神经的缺血和水肿具有预防作用。提供大鼠模型用于筛选能够改善视网膜功能障碍的化合物。特别地，可以筛选钙进入阻滞剂和兴奋性氨基酸拮抗剂，并且主机眼睛检查药物的作用。模型动物是由于导致缺血的血管闭塞而具有盐诱导性视网膜功能障碍和/或视网膜功能障碍的大鼠。

2. 发明申请

WO1994012634A1 NEUROTROPHIC FACTOR 审中-公开
标题翻译：神经营养因子
公开(公告)号：WO1994012634A1
公开(公告)日：1994-06-09
申请号：PCT/US1992010117
申请日：1992-11-24
申请人： HOUSTON BIOTECHNOLOGY INCORPORATED , WALLACE, Thomas, L. , POTTER, David, E.
发明人： HOUSTON BIOTECHNOLOGY INCORPORATED
IPC分类号： C12N15/12
CPC分类号： C07K14/475 , A61K38/00
摘要： Neurotrophic factor compositions are provided, obtainable from porcine lung tissue. Neurotrophic factor is active on parasympathetic ganglion neurons, enhancing survival of the neurons and increasing choline acetyltransferase activity.
摘要翻译：提供了从猪肺组织获得的神经营养因子组合物。神经营养因子对副交感神经节神经元有活性，增强神经元的存活和增加胆碱乙酰转移酶的活性。

3. 发明申请

WO1990006118A1 THERAPEUTIC USE OF DIHYDROPYRIMIDONES AND BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES IN RETINAL OR OPTIC NERVE DYSFUNCTION 审中-公开
标题翻译：二氢嘧啶酮和苯并嗪和苯并噻吩衍生物在神经或神经功能的治疗方法
公开(公告)号：WO1990006118A1
公开(公告)日：1990-06-14
申请号：PCT/US1989005505
申请日：1989-12-05
申请人： HOUSTON BIOTECHNOLOGY INCORPORATED , E.R. SQUIBB & SONS, INC. , CROSSON, Craig, E. , POTTER, David, E. , ONDETTI, Miguel, A. , FLOYD, David , ABERG, Gunner
发明人： HOUSTON BIOTECHNOLOGY INCORPORATED , E.R. SQUIBB & SONS, INC.
IPC分类号： A61K31/55
CPC分类号： A61K31/275 , A61K31/00 , A61K31/44 , A61K31/495 , A61K31/505 , A61K31/55 , A61K31/66
摘要： Ischemia or edema of the retina or optic nerve results in retinal dysfunction. This retinal dysfunction can be associated with the activation of calcium channels. The prophylactic or therapeutic administration of compounds to block these processes can ameliorate or prevent retinal dysfunction. These compounds include the dihydropyrimidones, benzazepine and benzothiazepine derivative classes selected of calcium channel antagonists. Therapeutic treatment with compounds include dihydropyrimidones and benzazepines and benzothiazepine derivatives as calcium channel antagonists. Such compounds exhibit a prophylactic effect to ischemia and edema of the retina or optic nerve.
摘要翻译：视网膜或视神经缺血或水肿导致视网膜功能障碍。这种视网膜功能障碍可能与钙通道的激活有关。阻止这些过程的化合物的预防或治疗性给药可以改善或预防视网膜功能障碍。这些化合物包括选自钙通道拮抗剂的二氢嘧啶酮，苯并氮杂和苯并硫氮杂衍生物类。用化合物的治疗性治疗包括二氢嘧啶酮和苯并氮杂和苯并硫氮杂衍生物作为钙通道拮抗剂。这些化合物对视网膜或视神经的缺血和水肿具有预防作用。

4. 发明申请

WO2017139382A1 COMBINATION OF ADJUVANT DRUGS ESKETAMINE AND BRIMONIDINE FOR MEDICAL TREATMENTS 审中-公开
标题翻译：辅助药物ESKETAMINE和BRIMONIDINE联合用于医疗治疗
公开(公告)号：WO2017139382A1
公开(公告)日：2017-08-17
申请号：PCT/US2017/017022
申请日：2017-02-08
申请人： THE TEXAS A&M UNIVERSITY SYSTEM , POTTER, David E. , SCHAPIRO (HOOK), Michelle A.
发明人： POTTER, David E. , SCHAPIRO (HOOK), Michelle A.
IPC分类号： A61K45/06 , A61K31/135
CPC分类号： A61K31/135 , A61K9/0019 , A61K9/1652 , A61K31/498 , G01N33/9486 , A61K2300/00
摘要： The invention disclosed herein generally relates to compositions and methods related to a combination of adjuvant drugs for medical treatments. The present invention relates to combining the adjuvant drugs esketamine and brimonidine to treat medical conditions such as pain, depression and hearing loss.
摘要翻译：本文公开的发明总体上涉及与用于医学治疗的辅助药物的组合相关的组合物和方法。本发明涉及将佐剂药物艾氯胺酮和溴莫尼定组合以治疗诸如疼痛，抑郁症和听力丧失的医学病症。

5. 发明申请

WO2004050065A1 INTRAOCULAR DELIVERY COMPOSITIONS AND METHODS 审中-公开
标题翻译：内分泌物组合物和方法
公开(公告)号：WO2004050065A1
公开(公告)日：2004-06-17
申请号：PCT/US2003/036335
申请日：2003-11-13
申请人： BIOSANTE PHARMACEUTICALS, INC. , CHU, Teh-Ching , POTTER, David, E.
发明人： CHU, Teh-Ching , POTTER, David, E. , BELL, Steve, J., D. , HE, Qing
IPC分类号： A61K9/16
CPC分类号： A61K9/5115 , A61K9/0034 , A61K9/0043 , A61K9/0048 , A61K9/1611 , A61K9/1676 , A61K9/51 , A61K9/5161 , A61K9/5192
摘要： The present invention relates to intraocular drug delivery for treating ocular diseases. Particularly, the invention relates to particles useful for the delivery of certain pharmacologically active agents to treat ocular diseases. The particles contain calcium phosphate core particles, particularly nanoparticles, as delivery agents and adjuvants. The invention also relates to methods of making such particles and to methods of treating ocular disease by delivery of a therapeutic drug to an ocular surface using the particles of this invention. The invention further relates to methods of regulating ocular pressure using certain formulations according to the present invention.
摘要翻译：本发明涉及用于治疗眼部疾病的眼内药物递送。特别地，本发明涉及可用于递送某些药理活性剂以治疗眼部疾病的颗粒。颗粒含有磷酸钙核心颗粒，特别是纳米颗粒，作为递送剂和助剂。本发明还涉及制备这种颗粒的方法以及使用本发明的颗粒将治疗药物递送至眼表面来治疗眼部疾病的方法。本发明还涉及使用根据本发明的某些制剂调节眼压的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式